Lane RM, Kordasiewicz HB, Smith AE, Mignon L, Miller T, Narayanan P, Swayze EE, Norris DA, Fitzsimmons B, Bennett CF. Rationale for and Development of IONIS-MAPTRx, the First Tau-lowering Antisense Oligonucleotide, in Patients with Mild AD. 1 Ionis Pharmaceuticals, 2017 ANA POSTER #M158
Recommends
Please login to recommend the paper.
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.